01888nas a2200421   4500000000100000008004100001260001300042653002700055653001000082653001600092653001500108653002900123653002400152653001100176653001100187653001300198653001200211653002000223653002600243653001600269653000900285653001600294653002400310653002200334653001500356653002000371100001400391700001500405700002100420700001700441700001700458700001600475245009300491300001100584490000700595520085000602022001401452       1985                            d  c1985 Dec10aAdjuvants, Immunologic10aAdult10aBCG Vaccine10aCimetidine10aClinical Trials as Topic10aDouble-Blind Method10aFemale10aHumans10aLepromin10aleprosy10aLeukocyte Count10aLymphocyte Activation10aLymphocytes10aMale10aMiddle Aged10aPhytohemagglutinins10aRandom Allocation10aSkin Tests10aTuberculin Test1 aBrown A E1 aNelson K E1 aMakonkawkeyoon S1 aVithayasai V1 aScollard D M1 aBullock W E00aA study of the immunological effects of cimetidine in patients with lepromatous leprosy.  a559-640 v533 a<p>To test the capacity of cimetidine to enhance cellular immunity in patients with lepromatous leprosy (LL), cimetidine was given for one month to 29 inactive LL patients and 3 active LL patients. Immune function was monitored with skin tests (lepromin, PPD, candida, and trichopytin), lymphocyte transformation tests (phytohemagglutinin, BCG, and Dharmendra lepromin), and quantitation of peripheral blood lymphocyte subpopulations. A small but significant "booster" response to PPD was the only change observed in the study of patients with inactive disease, and leprosy-related reactions did not occur. In the few active LL patients studied, neither immune enhancement nor leprosy-related reactions were observed. The results of this investigation suggest that cimetidine can be used safely in patients with inactive lepromatous leprosy.</p>  a0148-916X